Drug intelligence / Profile preview

IVAC

Development stage: Phase 1
Lead developer: SLK Kliniken Heilbronn
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

**IVAC** is an individualized therapeutic neoantigen peptide vaccine developed by SLK Kliniken Heilbronn for advanced or metastatic renal cell carcinoma. Each patient-specific vaccine is designed using tumor and matched-normal sequencing to identify mutations, followed by selection of HLA-binding peptides derived from mutated proteins. In IVAC-RCC-001, IVAC was evaluated as an add-on to nivolumab maintenance after ipilimumab plus nivolumab induction, with the intended effect of inducing de novo tumor-neoantigen-specific T-cell responses. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05641545))

Targets

Neoantigen (Tumor neoantigen)

Beyond the preview

Go deeper on IVAC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVAC.

Explore the full profile